Protocol Ledger

NCT03437785 · Phase II · COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

Interventional Phase II clinical trial protocol NCT03437785 sponsored by Chong Kun Dang Pharmaceutical in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-16 Enrollment: 250 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03437785
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03437785
Protocol FieldVerified Registry Value
NCT IdentifierNCT03437785
Consolidated Lead SponsorChong Kun Dang Pharmaceutical
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment250 participants (ACTUAL)
Registered Start Date2018-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03437785
Hospital Research SiteLocationSite Profile
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->
Kyungpook National University HospitalDaegu, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI